NEJM Interviews
Insightful conversations with leading experts in the field of health care, medical research, policy, and more from the New England Journal of Medicine (NEJM). Each episode examines the many complexities found at the junction of medicine and society.
Latest episodes
Sep 18, 2024 • 12min
NEJM Interview: Charles Weijer on the potential benefits and ethical challenges associated with pragmatic and cluster RCTs.
Charles Weijer is a professor in the Departments of Medicine and Philosophy at Western University. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. C. Weijer and M. Taljaard. Ethical Challenges Associated with Pragmatic and Cluster RCTs. N Engl J Med 2024;391:969-971.
Sep 15, 2024 • 3min
NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
Sep 15, 2024 • 3min
NEJM at ESMO — Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
Sep 14, 2024 • 3min
NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
Sep 14, 2024 • 3min
NEJM at ESMO — Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
Sep 14, 2024 • 4min
NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
Sep 14, 2024 • 4min
NEJM at ESMO — Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
Sep 14, 2024 • 3min
NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
Sep 13, 2024 • 3min
NEJM at ESMO — Ponsegromab in Cancer Cachexia
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
Sep 13, 2024 • 2min
NEJM at ESMO — Pembrolizumab in HER2+ Gastric Cancer
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
